Celldex Presents Results from Phase 1 Studies of CDX-1307 with GM-CSF
November 1st, 2008Celldex Therapeutics, Inc. (NASDAQ: CLDX - News) announced initial results from multi-center Phase 1 clinical trials of its cancer vaccine candidate, CDX-1307, combined with GM-CSF, at the International Society for the Biologic Therapy of Cancer (iSBTc) annual meeting in San Diego. These data provide the basis for the ongoing assessment of CDX-1307 combined with more [...]
































